According to Cohen the application relates to cell line expansion represents a fundamental improvement in the efficiency of producing stem cells which should have applications far beyond the cardiac therapy to which the present application relates.
Proteonomix president Michael Cohen said that this is another step in the development of their intellectual property and getting StromaCel into the commercial market.
"The technology covered by the patent application will reduce the cost to the patient of this type of treatment and when trials are completed and regulatory approvals are obtained we believe that the stromal cell technology we announce today will have major importance in the treatment of cardiac damage caused by heart attacks," Cohen said.